Literature DB >> 19861897

PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.

Angela Michelucci1, Claudio Di Cristofano, Azzurra Lami, Paola Collecchi, Adelaide Caligo, Nicola Decarli, Martina Leopizzi, Paolo Aretini, Gloria Bertacca, Romana Prosperi Porta, Sergio Ricci, Carlo Della Rocca, Giorgio Stanta, Generoso Bevilacqua, Andrea Cavazzana.   

Abstract

The PI3K-Akt cascade is a key signaling pathway involved in cell proliferation, survival, and growth. Activating PIK3CA mutations have been reported in breast carcinoma (BC). The aim of this study was to characterize the PIK3CA mutations at exons 9 and 20 in a series of 176 sporadic and 22 hereditary BCs and to correlate the results with clinicopathologic parameters and survival. In sporadic BC, 68 missense mutations were detected. PIK3CA mutations were significantly associated with ER+ in HER2-negative cases. A higher frequency of PIK3CA mutations was present in lobular carcinoma compared with ductal carcinoma (50% vs. 35%). There was no association between the survival and PIK3CA mutational status. In hereditary BC, PIK3CA mutations were found only in the BRCA2 group. The PIK3CA mutation seems to characterize the luminal-type BC, in both sporadic and BRCA2 mutated forms, and is absent in the basal-type BC, in both the sporadic and BRCA1 mutated forms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861897     DOI: 10.1097/PDM.0b013e31818e5fa4

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  20 in total

1.  PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Authors:  Lucia Veronica Cuorvo; Paolo Verderio; Chiara Maura Ciniselli; Salvatore Girlando; Nicola Decarli; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Claudio Eccher; Chiara Cantaloni; Francesco Mauri; Michael Seckl; Marco Volante; Fiamma Buttitta; Antonio Marchetti; Quattrone Silvia; Enzo Galligioni; Paolo Dalla Palma; Mattia Barbareschi
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

2.  Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.

Authors:  Aggeliki Tserga; Ilenia Chatziandreou; Nicolaos V Michalopoulos; Efstratios Patsouris; Angelica A Saetta
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

3.  PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

Authors:  Mattia Barbareschi; Lucia Veronica Cuorvo; Salvatore Girlando; Emma Bragantini; Claudio Eccher; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Chiara Cantaloni; Nicola Decarli; Enzo Galligioni; Paolo Dalla Palma
Journal:  Virchows Arch       Date:  2012-06-29       Impact factor: 4.064

4.  Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population.

Authors:  Kandarpa Kumar Saikia; Manoj Kumar Panigrahi; Anurag Mehta; Dushyant Kumar
Journal:  Indian J Surg Oncol       Date:  2018-05-03

5.  Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.

Authors:  Bedri Karakas; Dilek Colak; Namik Kaya; Hazem Ghebeh; Abeer Al-Qasem; Fawziah Hendrayani; Mohamed Toulimat; Taher Al-Tweigeri; Ben Ho Park; Abdelilah Aboussekhra
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

Review 6.  Breast cancer genomes--form and function.

Authors:  James Korkola; Joe W Gray
Journal:  Curr Opin Genet Dev       Date:  2010-01-07       Impact factor: 5.578

7.  Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1.

Authors:  Fumiko Kito; Rieko Oyama; Rei Noguchi; Emi Hattori; Marimu Sakumoto; Makoto Endo; Eisuke Kobayashi; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-10-17       Impact factor: 4.174

Review 8.  The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.

Authors:  Amaury G Dumont; Sarah N Dumont; Jonathan C Trent
Journal:  Chin J Cancer       Date:  2012-05-24

9.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

Authors:  Magdalena Cizkova; Aurélie Susini; Sophie Vacher; Géraldine Cizeron-Clairac; Catherine Andrieu; Keltouma Driouch; Emmanuelle Fourme; Rosette Lidereau; Ivan Bièche
Journal:  Breast Cancer Res       Date:  2012-02-13       Impact factor: 6.466

10.  PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.

Authors:  Flavia R Mangone; Irina G Bobrovnitchaia; Sibeli Salaorni; Erika Manuli; Maria A Nagai
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.